Author | Lisette Hilton

Articles

Enzalutamide reduces risk of death in men with nmCRPC by 27% vs placebo

June 01, 2020

This final analysis of the phase 3 PROSPER study supports enzalutamide and androgen deprivation therapy as the standard of care to improve overall survival in prostate cancer patients before the onset of detectable metastasis.

Apalutamide plus ADT improves OS in men with non-metastatic castration-resistant PCa

June 01, 2020

Apalutamide (ERLEADA) combined with androgen deprivation therapy improves overall survival more than androgen deprivation therapy alone in men with non-metastatic castration-resistant prostate cancer at high risk of metastases, according to results from investigators’ final analysis of the phase 3 SPARTAN trial.